Flexion Therapeutics Inc (FLXN) Expected to Post Quarterly Sales of $9.40 Million

Equities analysts expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will announce sales of $9.40 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Flexion Therapeutics’ earnings, with estimates ranging from $9.30 million to $9.50 million. Flexion Therapeutics reported sales of $360,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 2,511.1%. The business is expected to announce its next earnings results on Thursday, March 14th.

On average, analysts expect that Flexion Therapeutics will report full year sales of $22.48 million for the current financial year. For the next year, analysts anticipate that the company will post sales of $71.20 million, with estimates ranging from $60.00 million to $81.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.09. The business had revenue of $6.99 million for the quarter, compared to analyst estimates of $5.93 million. Flexion Therapeutics had a negative net margin of 1,346.87% and a negative return on equity of 88.21%.

Several brokerages recently issued reports on FLXN. BidaskClub raised shares of Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, January 5th. ValuEngine raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 16th. Wells Fargo & Co reissued a “buy” rating and set a $26.00 price objective on shares of Flexion Therapeutics in a report on Friday, December 28th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective (down from $42.00) on shares of Flexion Therapeutics in a report on Friday, January 4th. Finally, Zacks Investment Research raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Monday, December 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $27.08.

In other news, CFO David Arkowitz bought 4,000 shares of the stock in a transaction on Friday, November 9th. The stock was bought at an average cost of $16.56 per share, for a total transaction of $66,240.00. Following the completion of the purchase, the chief financial officer now directly owns 48,250 shares in the company, valued at $799,020. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction on Friday, November 9th. The stock was purchased at an average price of $17.10 per share, with a total value of $85,500.00. Following the completion of the purchase, the insider now owns 83,295 shares of the company’s stock, valued at $1,424,344.50. The disclosure for this purchase can be found here. 14.59% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Carroll Financial Associates Inc. boosted its stake in Flexion Therapeutics by 100.0% in the fourth quarter. Carroll Financial Associates Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,000 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Flexion Therapeutics during the third quarter worth $217,000. Redmile Group LLC lifted its stake in shares of Flexion Therapeutics by 33.5% during the second quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 3,330 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in shares of Flexion Therapeutics by 22.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock worth $411,000 after buying an additional 2,960 shares during the period. Finally, MetLife Investment Advisors LLC lifted its stake in shares of Flexion Therapeutics by 52.1% during the third quarter. MetLife Investment Advisors LLC now owns 23,602 shares of the specialty pharmaceutical company’s stock worth $442,000 after buying an additional 8,084 shares during the period.

Shares of NASDAQ:FLXN traded up $0.02 during trading on Friday, reaching $13.24. 307,200 shares of the company were exchanged, compared to its average volume of 1,013,463. The firm has a market cap of $493.65 million, a PE ratio of -3.18 and a beta of 1.54. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.74 and a current ratio of 8.88. Flexion Therapeutics has a 12-month low of $10.98 and a 12-month high of $29.10.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Article: Treasury Bonds

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply